uploads/2018/03/Womens-Health-1.png

How Merck’s Women’s Health Segment Performed in 2017

By

Updated

Implanon-Nexplanon revenue trends

In 4Q17, Merck’s (MRK) Implanon-Nexplanon reported revenues of $183 million, which was ~14% higher on a YoY (year-over-year) basis and a ~18% rise on a QoQ (quarter-over-quarter) basis.

In 4Q17, in the US and in international markets, Implanon-Nexplanon reported revenues of $129 million and $54 million, respectively, compared with $112 million and $48 million in 4Q16, which was ~15% higher and ~12% higher, respectively, on a YoY basis.

Article continues below advertisement

In fiscal 2017, Implanon-Nexplanon generated revenues of $686 million, which was ~13% higher YoY. In 2017, in the US and in international markets, Implanon-Nexplanon reported revenues of $496 million and $191 million, respectively, compared with $420 million and $186 million in 2016, which was ~18% higher and ~2% higher, respectively, YoY.

In the marketplace, Nexplanon’s notable peers include Allergan’s (AGN) Lo Loestrin Fe and Bayer’s (BAYZF) Mirena.

NuvaRing revenue trends

In 4Q17, NuvaRing reported revenues of $188 million, which was ~9% lower YoY and 12% lower QoQ. In 4Q17, in the US and in international markets, NuvaRing reported revenues of $139 million and $49 million, respectively, compared with $155 million and $52 million in 4Q16, which reflected a ~10% fall and a ~6% fall, respectively, YoY.

In fiscal 2017, NuvaRing reported revenues of $761 million, compared with $777 million in 2016, which represents a ~2% YoY decline. In 2017, in the US and in international markets, NuvaRing reported revenues of $564 million and $197 million, respectively, compared with $576 million and $202 million in 2016, which was ~2% lower and ~2% lower, respectively, YoY.

Follistim AQ revenue trends

In 4Q17, Follistim AQ generated revenues of $66 million, which represents a ~24% decline on a YoY basis and an 8% QoQ decline.

In 4Q17, in the US and in international markets, Follistim AQ reported revenues of $19 million and $47 million, respectively, compared with $36 million and $51 million in 4Q16, which was ~48% lower and ~9% lower, respectively, YoY.

In fiscal 2017, Follistim AQ reported revenues of $298 million, which reflected a ~16% YoY decline. In 2017, in the US and international markets, Follistim AQ generated revenues of $123 million and $174 million, respectively, compared with $157 million and $197 million in 2016, which represents a ~22% fall and a ~12% fall, respectively, YoY.

Advertisement

More From Market Realist